GPATCH11

Summary

GPATCH11 (G-patch domain containing 11, HGNC:26768) is a protein-coding gene on chromosome 2p22.2, encoding G patch domain-containing protein 11 (Q8N954).

Predicted to enable nucleic acid binding activity. Located in kinetochore.

Source: NCBI Gene 253635 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Strong, GenCC)
• Clinical variants (ClinVar): 51 total — 4 pathogenic
• MANE Select transcript: NM_174931

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26768
Approved symbol	GPATCH11
Name	G-patch domain containing 11
Location	2p22.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ38348, CENPY, CENP-Y
Ensembl gene	ENSG00000152133
Ensembl biotype	protein_coding
OMIM	621183
Entrez	253635

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 retained_intron

ENST00000281932, ENST00000473067, ENST00000674370, ENST00000964376, ENST00000964377

RefSeq mRNA: 9 — MANE Select: NM_174931 NM_001278505, NM_001322249, NM_001371856, NM_001371858, NM_001371859, NM_001371860, NM_001371861, NM_001371862, NM_174931

CCDS: CCDS1785

Canonical transcript exons

ENST00000674370 — 9 exons

Exon	Start	End
ENSE00001153301	37094082	37094195
ENSE00001213466	37095437	37095518
ENSE00001427985	37089640	37089866
ENSE00001480030	37090681	37090722
ENSE00001583953	37096208	37099244
ENSE00001951164	37084518	37084570
ENSE00003520100	37091916	37092036
ENSE00003617907	37092165	37092255
ENSE00003898684	37088369	37088440

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 90.07.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.1036 / max 832.5096, expressed in 1734 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
19749	14.3955	1715
19746	0.7146	296
19748	0.6097	307
202159	0.2651	121
19747	0.1187	50

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	90.07	gold quality
middle temporal gyrus	UBERON:0002771	87.46	gold quality
pancreatic ductal cell	CL:0002079	86.92	gold quality
tendon	UBERON:0000043	85.51	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.14	gold quality
endothelial cell	CL:0000115	84.85	gold quality
cardiac muscle of right atrium	UBERON:0003379	84.59	silver quality
adipose tissue	UBERON:0001013	84.25	gold quality
upper arm skin	UBERON:0004263	84.23	silver quality
postcentral gyrus	UBERON:0002581	83.69	gold quality
Brodmann (1909) area 23	UBERON:0013554	83.64	gold quality
superior frontal gyrus	UBERON:0002661	83.20	gold quality
myocardium	UBERON:0002349	83.16	silver quality
medial globus pallidus	UBERON:0002477	82.92	gold quality
subcutaneous adipose tissue	UBERON:0002190	82.74	gold quality
entorhinal cortex	UBERON:0002728	82.70	gold quality
lymph node	UBERON:0000029	82.67	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	82.67	gold quality
ventricular zone	UBERON:0003053	82.57	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.51	gold quality
corpus callosum	UBERON:0002336	82.40	gold quality
tendon of biceps brachii	UBERON:0008188	82.40	gold quality
parietal lobe	UBERON:0001872	82.32	gold quality
prefrontal cortex	UBERON:0000451	82.22	gold quality
primary visual cortex	UBERON:0002436	82.20	gold quality
spinal cord	UBERON:0002240	82.06	gold quality
globus pallidus	UBERON:0001875	81.54	gold quality
islet of Langerhans	UBERON:0000006	81.48	gold quality
cortical plate	UBERON:0005343	81.36	gold quality
ganglionic eminence	UBERON:0004023	81.23	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.20

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

157 targeting GPATCH11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-23B-5P	99.98	66.07	587
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-128-3P	99.95	71.17	2484

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	gpatch11	ENSDARG00000026892
mus_musculus	Gpatch11	ENSMUSG00000050668
rattus_norvegicus	Gpatch11	ENSRNOG00000025317
drosophila_melanogaster	CG10053	FBGN0037490
caenorhabditis_elegans		WBGENE00011451

Protein

Protein identifiers

G patch domain-containing protein 11 — Q8N954 (reviewed: Q8N954)

Alternative names: Centromeric protein Y, Coiled-coil domain-containing protein 75

All UniProt accessions (2): A0A6I8PRS5, A0A6Q8JGY2

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Chromosome. Centromere. Kinetochore.

Similarity. Belongs to the GPATCH11 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N954-1	1	yes
Q8N954-2	2

RefSeq proteins (9): NP_001265434, NP_001309178, NP_001358785, NP_001358787, NP_001358788, NP_001358789, NP_001358790, NP_001358791, NP_777591* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000467	G_patch_dom	Domain
IPR025239	DUF4187	Domain
IPR039249	GPATCH11	Family

Pfam: PF01585, PF13821

UniProt features (10 total): region of interest 2, modified residue 2, splice variant 2, chain 1, domain 1, coiled-coil region 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N954-F1	80.60	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 141, 149

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 97 (showing top): FXR_IR1_Q6, TGCGCANK_UNKNOWN, CEBP_Q2, GGCKCATGS_UNKNOWN, RYTTCCTG_ETS2_B, FISCHER_DREAM_TARGETS, YNGTTNNNATT_UNKNOWN, GOCC_CHROMOSOMAL_REGION, GOCC_CONDENSED_CHROMOSOME_CENTROMERIC_REGION, CEBPB_02, chr2p22, GOCC_SUPRAMOLECULAR_COMPLEX, NRF1_Q6, HHEX_TARGET_GENES, HOXB4_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (1): nucleic acid binding (GO:0003676)

GO Cellular Component (1): kinetochore (GO:0000776)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
condensed chromosome, centromeric region	1
intracellular membraneless organelle	1
supramolecular complex	1

Protein interactions and networks

STRING

1280 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPATCH11	YJU2B	P13994	580
GPATCH11	CCDC97	Q96F63	528
GPATCH11	GEM	P55040	510
GPATCH11	NRDC	O43847	494
GPATCH11	TTC27	Q6P3X3	456
GPATCH11	FN3KRP	Q9HA64	453
GPATCH11	U2SURP	O15042	451
GPATCH11	C4orf33	Q8N1A6	446
GPATCH11	CEP128	Q6ZU80	424
GPATCH11	CHERP	Q8IWX8	422
GPATCH11	CDKL4	Q5MAI5	417
GPATCH11	DRC1	Q96MC2	415
GPATCH11	TMEM255A	Q5JRV8	393
GPATCH11	ZNF276	Q8N554	391
GPATCH11	SF3A2	Q15428	379

IntAct

77 interactions, top by confidence:

A	B	Type	Score
SNRPF	GEMIN2	psi-mi:“MI:0914”(association)	0.910
SMNDC1	SF3B1	psi-mi:“MI:0914”(association)	0.790
SNRPE	GEMIN2	psi-mi:“MI:0914”(association)	0.770
RBM17	U2SURP	psi-mi:“MI:0914”(association)	0.740
SNRPD2	GEMIN2	psi-mi:“MI:0914”(association)	0.710
SNRPG	GEMIN2	psi-mi:“MI:0914”(association)	0.710
SNRPB	PRMT5	psi-mi:“MI:0914”(association)	0.670
SNRPA1	HTATSF1	psi-mi:“MI:0914”(association)	0.640
DNAJC8	SF3B1	psi-mi:“MI:0914”(association)	0.640
SF3B1	SAP18	psi-mi:“MI:0914”(association)	0.640
KPNA1	TCERG1	psi-mi:“MI:0914”(association)	0.640
SNRPA1	U2SURP	psi-mi:“MI:0914”(association)	0.640
GPATCH11	ADGRB3	psi-mi:“MI:0915”(physical association)	0.560
SDCBP	GPATCH11	psi-mi:“MI:0915”(physical association)	0.560
ADGRB3	GPATCH11	psi-mi:“MI:0915”(physical association)	0.560
H1-6	ZNF724	psi-mi:“MI:0914”(association)	0.530
SNRPE	PRMT5	psi-mi:“MI:0914”(association)	0.530
SNRPN	PRMT5	psi-mi:“MI:0914”(association)	0.530
SF3A3	SF3B1	psi-mi:“MI:0914”(association)	0.530
SNRPE	SNRPGP15	psi-mi:“MI:0914”(association)	0.530
SNRPF	SNRPGP15	psi-mi:“MI:0914”(association)	0.530
U2AF2	U2SURP	psi-mi:“MI:0914”(association)	0.480
SMNDC1	U2SURP	psi-mi:“MI:0914”(association)	0.480
GPATCH11	RPLP2	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (78): GPATCH11 (Two-hybrid), GPATCH11 (Two-hybrid), GPATCH11 (Affinity Capture-RNA), GPATCH11 (Affinity Capture-MS), GPATCH11 (Affinity Capture-MS), GPATCH11 (Affinity Capture-MS), GPATCH11 (Proximity Label-MS), GPATCH11 (Affinity Capture-MS), GPATCH11 (Affinity Capture-MS), GPATCH11 (Affinity Capture-MS), GPATCH11 (Affinity Capture-MS), GPATCH11 (Affinity Capture-MS), GPATCH11 (Affinity Capture-MS), GPATCH11 (Affinity Capture-MS), GPATCH11 (Affinity Capture-MS)

ESM2 similar proteins: A3KMI0, A7SBN6, B3MPC0, B3N8L3, B4G7U3, B4HWD7, B4JCG4, B4KH32, B4M9F7, B4NYQ2, B4Q8A7, C0HAV3, E7EXT2, E9PZM4, O13747, O14647, O75940, P87143, Q09655, Q0IIX9, Q17CQ8, Q29NF3, Q2KI19, Q3T045, Q3UFS4, Q4QQU6, Q5R591, Q5RET3, Q5U2Y6, Q5U4Z3, Q6DEY1, Q6DF57, Q6DGZ0, Q6K687, Q6PD74, Q7PYU6, Q7SXW2, Q7ZV80, Q8BGT7, Q8N954

Diamond homologs: A0JMV4, A4IGK4, A5DEF8, A5DSB5, A6ZRL6, A7TQN2, O74363, P53866, Q3UFS4, Q59UG4, Q6BYP9, Q6CQ59, Q6DDU9, Q6DF57, Q6FP19, Q75E62, Q7TN31, Q7TQC7, Q875B6, Q8N302, Q8N954, Q9NW75, A2VE39, A4HQI9, A8XYX2, A8XYX3, D2HRF1, P0C967, P0C968, P0C969, P0C970, P41469, Q2KI19, Q38AH0, Q4E123, Q4Q089, Q54WR1, Q5R981, Q5RAY7, Q5U2Z5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 79 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Metabolism of non-coding RNA	6	63.4×	9e-09
mRNA Splicing - Minor Pathway	11	41.0×	5e-14
mRNA Splicing	22	40.3×	1e-28
mRNA Polyadenylation	26	38.1×	2e-33
SARS-CoV-2 modulates host translation machinery	10	37.3×	3e-12
CHD1 and CHD2 subfamily	20	36.2×	5e-25
Processing of Capped Intron-Containing Pre-mRNA	23	31.5×	1e-27
mRNA Splicing - Major Pathway	30	27.3×	2e-34

GO biological processes:

GO term	Partners	Fold	FDR
U2-type prespliceosome assembly	17	149.4×	2e-32
spliceosomal complex assembly	8	67.8×	2e-11
spliceosomal snRNP assembly	7	57.3×	2e-09
negative regulation of mRNA splicing, via spliceosome	5	53.9×	1e-06
RNA splicing, via transesterification reactions	6	52.7×	6e-08
mRNA splicing, via spliceosome	24	31.0×	1e-27
RNA splicing	16	19.9×	9e-15
ribosomal small subunit biogenesis	5	16.0×	5e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	0
Uncertain significance	38
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
3062155	NM_174931.4(GPATCH11):c.328+1G>T	Pathogenic
3062156	NM_174931.4(GPATCH11):c.454C>T (p.Arg152Ter)	Pathogenic
3062157	NM_174931.4(GPATCH11):c.449+1G>C	Pathogenic
3062158	NM_174931.4(GPATCH11):c.393C>G (p.Tyr131Ter)	Pathogenic

SpliceAI

1068 predictions. Top by Δscore:

Variant	Effect	Δscore
2:37084569:AG:A	donor_loss	1.0000
2:37088436:GTCCA:G	donor_gain	1.0000
2:37088441:G:GG	donor_gain	1.0000
2:37089639:GAGAA:G	acceptor_gain	1.0000
2:37089779:TTG:T	donor_gain	1.0000
2:37089862:GAGTG:G	donor_gain	1.0000
2:37089864:GTG:G	donor_gain	1.0000
2:37090678:AAGGG:A	acceptor_gain	1.0000
2:37090679:AGGG:A	acceptor_gain	1.0000
2:37090680:GGGG:G	acceptor_gain	1.0000
2:37091914:A:AG	acceptor_gain	1.0000
2:37091914:A:C	acceptor_loss	1.0000
2:37091914:AG:A	acceptor_gain	1.0000
2:37091914:AGG:A	acceptor_gain	1.0000
2:37091915:G:A	acceptor_loss	1.0000
2:37091915:G:GA	acceptor_gain	1.0000
2:37091915:GG:G	acceptor_gain	1.0000
2:37091915:GGG:G	acceptor_gain	1.0000
2:37091915:GGGA:G	acceptor_gain	1.0000
2:37092032:T:G	donor_gain	1.0000
2:37092033:TTCGG:T	donor_loss	1.0000
2:37092035:CGGT:C	donor_loss	1.0000
2:37092036:GGT:G	donor_loss	1.0000
2:37092037:G:C	donor_loss	1.0000
2:37092037:G:GG	donor_gain	1.0000
2:37092038:T:A	donor_loss	1.0000
2:37092159:A:AG	acceptor_gain	1.0000
2:37092160:A:G	acceptor_gain	1.0000
2:37092161:TTA:T	acceptor_loss	1.0000
2:37092162:TAG:T	acceptor_loss	1.0000

AlphaMissense

1757 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:37089822:T:C	L103P	0.999
2:37095491:T:C	C259R	0.999
2:37092212:T:C	L188P	0.998
2:37092220:A:C	S191R	0.998
2:37092222:C:A	S191R	0.998
2:37092222:C:G	S191R	0.998
2:37095493:T:G	C259W	0.998
2:37095500:T:A	C262S	0.998
2:37095500:T:C	C262R	0.998
2:37095501:G:C	C262S	0.998
2:37096231:T:C	C276R	0.998
2:37089822:T:A	L103H	0.997
2:37092242:T:C	L198P	0.997
2:37095492:G:A	C259Y	0.997
2:37095497:T:A	W261R	0.997
2:37095497:T:C	W261R	0.997
2:37096231:T:A	C276S	0.997
2:37096232:G:C	C276S	0.997
2:37096233:T:G	C276W	0.997
2:37089768:G:C	R85P	0.996
2:37095491:T:A	C259S	0.996
2:37095492:G:C	C259S	0.996
2:37095501:G:A	C262Y	0.996
2:37095501:G:T	C262F	0.996
2:37089836:T:G	Y108D	0.995
2:37092224:A:C	Q192P	0.995
2:37092232:T:C	C195R	0.995
2:37092234:T:G	C195W	0.995
2:37095492:G:T	C259F	0.995
2:37095499:G:C	W261C	0.995

dbSNP variants (sampled 300 via entrez): RS1000151344 (2:37083994 A>C,G), RS1000466203 (2:37095153 A>T), RS1001045148 (2:37082912 G>A,C,T), RS1001559663 (2:37082736 G>A), RS1001658554 (2:37083736 C>A,T), RS1001682558 (2:37093928 T>C), RS1001903623 (2:37098517 G>GAGTT), RS1002957660 (2:37092469 T>TCA), RS1003580220 (2:37097187 G>C), RS1003666734 (2:37094897 C>T), RS1003714825 (2:37088510 T>G), RS1003743280 (2:37091228 G>A,T), RS1003928114 (2:37084465 T>C,G), RS1004064046 (2:37084695 G>A,C), RS1004137877 (2:37096017 C>T)

Disease associations

OMIM: gene MIM:621183 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Strong	Autosomal recessive

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
FR900359	decreases phosphorylation	1
bisphenol F	affects cotreatment, affects expression	1
triphenyl phosphate	affects expression	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	affects expression	1
resorcinol	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	increases reaction, affects binding	1
bisphenol S	affects cotreatment, decreases expression	1
MT19c compound	increases expression	1
Coumestrol	increases expression	1
Demecolcine	decreases expression	1
Dexamethasone	affects cotreatment, affects expression, decreases expression	1
Indomethacin	decreases expression, affects cotreatment, affects expression	1
Methyl Methanesulfonate	increases expression	1
Sodium Dodecyl Sulfate	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1
Urethane	increases expression	1
Vincristine	decreases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, affects expression, decreases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	1
Gold Compounds	decreases expression	1
Sodium Selenite	decreases expression	1
Copper Sulfate	affects expression	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice